Literature DB >> 26134457

Long-Term Clinical Outcomes of True and Non-True Bifurcation Lesions According to Medina Classification- Results From the COBIS (COronary BIfurcation Stent) II Registry.

Taek Kyu Park1, Yong Hwan Park, Young Bin Song, Ju Hyeon Oh, Woo Jung Chun, Gu Hyun Kang, Woo Jin Jang, Joo-Yong Hahn, Jeong Hoon Yang, Seung-Hyuk Choi, Jin-Ho Choi, Sang Hoon Lee, Myung-Ho Jeong, Hyo-Soo Kim, Jae-Hwan Lee, Cheol Woong Yu, Seung Woon Rha, Yangsoo Jang, Jung Han Yoon, Seung-Jea Tahk, Ki Bae Seung, Jong-Seon Park, Hyeon-Cheol Gwon.   

Abstract

BACKGROUND: Little is known about the clinical outcomes of patients with different types of coronary bifurcation lesions. We sought to compare long-term clinical outcomes of patients with true or non-true bifurcation lesions who underwent percutaneous coronary intervention. METHODS AND 
RESULTS: We compared major adverse cardiac events (MACE: cardiac death, myocardial infarction [MI], or target lesion revascularization) between 1,502 patients with true bifurcation lesions (51.8%) and 1,395 with non-true bifurcation lesions (48.2%). True bifurcation lesions were defined as Medina classification (1.1.1), (1.0.1), or (0.1.1) lesions. During a median follow-up of 36 months, MACE occurred in 296 (10.2%) patients. Patients with true bifurcation lesions had a significantly higher risk of MACE than those with non-true bifurcation lesions (HR 1.39; 95% CI 1.08-1.80; P=0.01). Among true bifurcation lesions, Medina (1.1.1) and (0.1.1) were associated with a higher risk of cardiac death or MI than Medina (1.0.1) (HR 4.15; 95% CI 1.01-17.1; P=0.05). During the procedure, side branch occlusion occurred more frequently in Medina (1.1.1) and (1.0.1) than Medina (0.1.1) lesions (11.5% vs. 7.4%, P=0.03).
CONCLUSIONS: Patients with true bifurcation lesions had worse clinical outcomes than those with non-true bifurcation lesions. Procedural and long-term clinical outcomes differed according to the type of bifurcation lesion. These findings should be considered in future bifurcation studies.

Entities:  

Mesh:

Year:  2015        PMID: 26134457     DOI: 10.1253/circj.CJ-15-0264

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  12 in total

1.  Impact of directional coronary atherectomy followed by drug-coated balloon strategy to avoid the complex stenting for bifurcation lesions.

Authors:  Masaaki Okutsu; Satoru Mitomo; Toru Ouchi; Hisahito Yuki; Takahiro Ueno; Hirokazu Onish; Hiroto Yabushita; Satoshi Matsuoka; Hiroyoshi Kawamoto; Yusuke Watanabe; Kentaro Tanaka; Toru Naganuma; Tomohiko Sato; Satoko Tahara; Naoyuki Kurita; Shotaro Nakamura; Sunao Nakamura
Journal:  Heart Vessels       Date:  2022-01-04       Impact factor: 2.037

2.  Customizable Angioplasty Balloon-Forming Machine: Towards Precision Medicine in Coronary Bifurcation Lesion Interventions.

Authors:  Kaitlyn M Elmer; Maxwell J Bean; Barry F Uretsky; Sam E Stephens; Hanna K Jensen; Morten O Jensen
Journal:  J Cardiovasc Transl Res       Date:  2022-03-21       Impact factor: 4.132

3.  Paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease in elective clinical practice.

Authors:  Vassilios S Vassiliou; Simon C Eccleshall; Ioannis Merinopoulos; Tharusha Gunawardena; Natasha Corballis; U Bhalraam; Tim Gilbert; Clint Maart; Paul Richardson; Alisdair Ryding; Toomas Sarev; Chris Sawh; Sreekumar Sulfi; Upul Wickramarachchi; Trevor Wistow; Mohamed O Mohamed; Mamas A Mamas
Journal:  Clin Res Cardiol       Date:  2022-09-14       Impact factor: 6.138

4.  Prognostic significance of the Medina classification in bifurcation lesion percutaneous coronary intervention with second-generation drug-eluting stents.

Authors:  Leor Perl; Guy Witberg; Gabriel Greenberg; Hana Vaknin-Assa; Ran Kornowski; Abid Assali
Journal:  Heart Vessels       Date:  2019-09-17       Impact factor: 2.037

5.  A randomised comparison of Conventional versus Intentional straTegy in patients with high Risk prEdiction of Side branch OccLusion in coronary bifurcation interVEntion: rationale and design of the CIT-RESOLVE trial.

Authors:  Dong Zhang; Dong Yin; Chenxi Song; Chengang Zhu; Ajay J Kirtane; Bo Xu; Kefei Dou
Journal:  BMJ Open       Date:  2017-06-12       Impact factor: 2.692

6.  Balloon-stent kissing technique versus jailed wire technique for interventional treatment of coronary bifurcation lesions: Comparison of short- and long-term clinical outcomes.

Authors:  Zhe Jin; Linlin Song; Zhenguo Zheng; Shuying Zhang; Meilan Wang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

7.  Modified balloon-stent kissing technique avoid side-branch compromise for simple true bifurcation lesions.

Authors:  Wen-Bo Qu; Wei Zhang; Jun-Yan Liu; Fan Zhang; Shuai-Nan Mu; Sheng-Ming Zhang; Hao Tang; Xi-Qian Liu; Xue-Qi Li; Bing-Chen Liu
Journal:  BMC Cardiovasc Disord       Date:  2019-04-08       Impact factor: 2.298

8.  Impact of glycemic control status on patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.

Authors:  Yan Li; Xiaowen Li; Yinhua Zhang; Leimin Zhang; Qingqing Wu; Zhaorun Bai; Jin Si; Xuebing Zuo; Ning Shi; Jing Li; Xi Chu
Journal:  BMC Cardiovasc Disord       Date:  2020-01-30       Impact factor: 2.298

9.  Percutaneous coronary intervention for bifurcation coronary lesions: the 15th consensus document from the European Bifurcation Club.

Authors:  Francesco Burzotta; Jens Flensted Lassen; Thierry Lefèvre; Adrian P Banning; Yiannis S Chatzizisis; Thomas William Johnson; Miroslaw Ferenc; Sudhir Rathore; Remo Albiero; Manuel Pan; Olivier Darremont; David Hildick-Smith; Alaide Chieffo; Marco Zimarino; Yves Louvard; Goran Stankovic
Journal:  EuroIntervention       Date:  2021-03-19       Impact factor: 6.534

10.  Intravascular ultrasound-guided percutaneous coronary intervention for patients with coronary bifurcation lesions: A systematic review and meta-analysis.

Authors:  Rong-Rong Yang; Yong-Hui Lv; Chen Guo; Min Li; Ming-Bo Zhang; Zhi-Lu Wang; Ying Meng
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.